Skip to content
AwardedPOLGoods

Koncentrat rekombinowanego wieprzowego czynnika krzepnięcia VIII wraz z dostawą do Regionalnych Centrów Krwiodawstwa i Krwiolecznictwa; znak postępowania: ZZP.ZP.411.82.2026

Published
Published 12 May 2026
Deadline
Closed 27 May 2026

Overview

Narodowe Centrum Krwi procured recombinant porcine factor VIII concentrate for the treatment of patients with acquired congenital hemophilia A, to be delivered to Regional Blood Donation and Treatment Centers across Poland. Takeda Pharma Sp. z o. o. was awarded the contract on 8 June 2026.

Key details

Country
POL
Status
Awarded
Category
Goods
Procedure
Open
Published
12 May 2026
Deadline
Closed
Classification (CPV)
Medicinal products for the blood and blood-forming organs

Award outcome

Award date
8 June 2026
Contract period
— → 30 September 2026
Winner
  • Takeda Pharma Sp. z o. o.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    9 July 2026

  2. Contract Notice

    20 May 2026

  3. Contract Notice

    11 May 2026

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Koncentrat rekombinowanego wieprzowego czynnika krzepnięcia VIII wraz z dostawą do Regionalnych Centrów Krwiodawstwa i Krwiolecznictwa; znak postępowania: ZZP.ZP.411.82.2026 — won by Takeda Pharma Sp. z o. o. — Skim